TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07036133: Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Mode

Sponsor: Acrotech Biopharma Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT07036133 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07036133 Rescue Dossier →